WHO Group 1 PAH is a rare subset of PH (pulmonary hypertension). Read about classification, survival rates, and prevalence of this serious, progressive disease.

Read about the nonspecific clinical characteristics of PAH and the criteria and testing needed to properly diagnose your patients.

PAH is a serious condition, but with early diagnosis and appropriate treatment, you might be able to improve your outcomes. PAH is also referred to as WHO Group 1 pulmonary hypertension.

PAH treatment guidelines provide a road map to managing your patients with PAH. The European Society of Cardiology (ESC) and European Respiratory Society (ERS) issued revised PAH care recommendations: 2022 ESC/ERS Guidelines for the Diagnosis …

If your healthcare provider finds 1 or more blood clot (s) in your lungs, they may determine you do not have group 1 pulmonary arterial hypertension (PAH), but a different kind of pulmonary …

Understand the importance of managing your PAH, assessing risk status and functional class, and the impact it can have on life expectancy.

This document provides an overview of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes that have been associated with pulmonary arterial hypertension (PAH), pulmonary hypertension (PH), and interstitial lung disease (ILD).

The PAH Initiative is dedicated to advancing patient care in pulmonary arterial hypertension (PAH). This initiative reflects United Therapeutics’ commitment to providing knowledge and inspiration based on science and research in PAH today.

Discusses how prognosis and survival rate of PAH patients can improve when patients achieve low-risk status, and how risk status can be determined by the use of risk score calculators.

PAH is the medical abbreviation that stands for pulmonary arterial hypertension. PAH is a serious disease that thickens and narrows the blood vessels in your lungs.